DECEMBER 6–10, 2022
Henry B. Gonzalez Convention Center
San Antonio, TX
Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.
Olufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.
A special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.
The forum, moderated by Steven Chmura, MD, PhD, will include two state-of-the-art presentations covering what is currently known about ablation of oligometastatic disease in breast cancer.
A panel of researchers and clinicians will join moderator Matthew Ellis, MB, BChir, BSc, PhD, FRCP, to review current evidence related to treatment strategies and outcomes for HER2-positive breast cancer.
Time is running out to visit the SABCS 2021 exhibit hall and explore the latest industry advancements in breast cancer prevention and care.
Industry exhibitors will showcase their latest breast cancer treatments, products, and technologies during five onsite presentations scheduled tomorrow.
Tuesday’s General Session featured presentations on abstracts that covered topics such as the clinical utility of molecular tumor profiling and imaging mass cytometry in triple-negative breast cancer.
A session on Tuesday explored how the effects of the pandemic will be felt throughout the breast cancer community for years to come.
In recognition of her trailblazing work in clinical cancer genetics, Judy E. Garber, MD, MPH, received the Susan G. Komen® Brinker Award for Scientific Distinction in Clinical Research on Tuesday.
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.